Reversibility of thrombin-induced decrease in platelet glycoprotein Ib function. 1993

H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
INSERM U 353, Hôpital Saint Louis, Paris, France.

Thrombin induces a redistribution of glycoprotein (GP) Ib/GP IX complex from the platelet surface into the surface connected canalicular system (SCCS). This redistribution results in a reduced interaction of platelet GP Ib with von Willebrand factor (vWF) bound to subendothelium leading to impaired platelet adhesion. In this study we show that the platelet aggregation and degranulation require concentrations of thrombin above 0.05 U/ml, while the decrease in GP Ib function (about 50% of control value), as determined by ristocetin induced platelet agglutination, can be induced by lower concentrations (0.01-0.04 U/ml). Moreover, we show that when adding thrombin inhibitors to the platelets preincubated with < 0.04 U/ml thrombin for 5 min, their agglutinability by ristocetin was gradually recovered within 30 min, indicating that in these conditions the decrease in platelet adhesiveness is reversible. Immuno-electromicroscopic study showed that this restoration of platelet GP Ib function was associated with a reversed translocation of GP Ib from the SCCS to the plasma membrane. The data obtained from counting gold particles showed that the ratio of GP Ib immunolabelling on the external membrane versus that on the SCCS was 3.31 +/- 0.90 for resting platelets, down-regulated to 0.84 +/- 0.13 (P < 0.05 versus resting platelets) for the platelets treated with 0.04 U/ml thrombin and returned to 2.63 +/- 2.21 (P > 0.05 versus resting platelets) after incubation for 30 min with hirudin. However, the translocation of GP Ib was poorly reversed by thrombin inhibitors when higher concentrations of thrombin were used which induced platelet aggregation and large extent of degranulation. We conclude that thrombin affects platelets in a dose dependent manner, and that at low concentrations the decrease in platelet GP Ib related function is a reversible phenomenon.

UI MeSH Term Description Entries
D010974 Platelet Aggregation The attachment of PLATELETS to one another. This clumping together can be induced by a number of agents (e.g., THROMBIN; COLLAGEN) and is part of the mechanism leading to the formation of a THROMBUS. Aggregation, Platelet
D010980 Platelet Membrane Glycoproteins Surface glycoproteins on platelets which have a key role in hemostasis and thrombosis such as platelet adhesion and aggregation. Many of these are receptors. PM-GP,Platelet Glycoprotein,Platelet Membrane Glycoprotein,PM-GPs,Platelet Glycoproteins,Glycoprotein, Platelet,Glycoprotein, Platelet Membrane,Glycoproteins, Platelet,Glycoproteins, Platelet Membrane,Membrane Glycoprotein, Platelet,Membrane Glycoproteins, Platelet,PM GP
D001792 Blood Platelets Non-nucleated disk-shaped cells formed in the megakaryocyte and found in the blood of all mammals. They are mainly involved in blood coagulation. Platelets,Thrombocytes,Blood Platelet,Platelet,Platelet, Blood,Platelets, Blood,Thrombocyte
D002478 Cells, Cultured Cells propagated in vitro in special media conducive to their growth. Cultured cells are used to study developmental, morphologic, metabolic, physiologic, and genetic processes, among others. Cultured Cells,Cell, Cultured,Cultured Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006384 Hemagglutination The aggregation of ERYTHROCYTES by AGGLUTININS, including antibodies, lectins, and viral proteins (HEMAGGLUTINATION, VIRAL). Hemagglutinations
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000991 Antithrombins Endogenous factors and drugs that directly inhibit the action of THROMBIN, usually by blocking its enzymatic activity. They are distinguished from INDIRECT THROMBIN INHIBITORS, such as HEPARIN, which act by enhancing the inhibitory effects of antithrombins. Antithrombin,Direct Antithrombin,Direct Antithrombins,Direct Thrombin Inhibitor,Direct Thrombin Inhibitors,Antithrombin, Direct,Antithrombins, Direct,Inhibitor, Direct Thrombin,Thrombin Inhibitor, Direct,Thrombin Inhibitors, Direct
D012310 Ristocetin An antibiotic mixture of two components, A and B, obtained from Nocardia lurida (or the same substance produced by any other means). It is no longer used clinically because of its toxicity. It causes platelet agglutination and blood coagulation and is used to assay those functions in vitro. Ristomycin
D013917 Thrombin An enzyme formed from PROTHROMBIN that converts FIBRINOGEN to FIBRIN. Thrombase,Thrombin JMI,Thrombin-JMI,Thrombinar,Thrombostat,alpha-Thrombin,beta,gamma-Thrombin,beta-Thrombin,gamma-Thrombin,JMI, Thrombin

Related Publications

H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
December 1991, The Journal of biological chemistry,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
January 1992, Seminars in thrombosis and hemostasis,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
January 1996, Seminars in thrombosis and hemostasis,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
April 2003, Journal of thrombosis and haemostasis : JTH,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
June 2001, The Journal of biological chemistry,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
November 1996, The Journal of laboratory and clinical medicine,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
November 2003, Trends in molecular medicine,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
February 2001, Proceedings of the National Academy of Sciences of the United States of America,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
January 1992, Seminars in thrombosis and hemostasis,
H Lu, and S Menashi, and I Garcia, and E M Cramer, and H Li, and D Tenza, and C De Romeuf, and J Soria, and C Soria
December 1992, Blood,
Copied contents to your clipboard!